Trials / Unknown
UnknownNCT03134118
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks |
Timeline
- Start date
- 2018-04-11
- Primary completion
- 2023-12-01
- Completion
- 2024-07-01
- First posted
- 2017-04-28
- Last updated
- 2023-02-21
Locations
20 sites across 6 countries: Belgium, France, Netherlands, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT03134118. Inclusion in this directory is not an endorsement.